# Hiroshige Yoshioka

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hiroshige-yoshioka/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,187 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 50 |
| i10-index | 128 |
| Last Known Institution | Kansai Medical University |
| OpenAlex ID | https://openalex.org/A5034733511 |
| ORCID iD | https://orcid.org/0000-0001-7724-0481 |
| Works | 357 |

## Researcher papers

- [Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial](https://scholariq.org/papers/alectinib-versus-crizotinib-in-patients-with-alk-positive-non-small-cell-lung/)
- [CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study](https://scholariq.org/papers/ch5424802-ro5424802-for-patients-with-alk-rearranged-advanced-non-small-cell/)
- [Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/prophylactic-cranial-irradiation-versus-observation-in-patients-with-extensive/)
- [Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/amivantamab-plus-lazertinib-in-previously-untreated-i-egfr-i-mutated-advanced/)
- [Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L](https://scholariq.org/papers/randomized-phase-iii-study-comparing-gefitinib-with-erlotinib-in-patients-with/)
- [The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV](https://scholariq.org/papers/the-japanese-lung-cancer-society-guideline-for-non-small-cell-lung-cancer-stage/)
- [Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study](https://scholariq.org/papers/efficacy-and-safety-of-nivolumab-in-previously-treated-patients-with-non-small/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Kansai Medical University](https://scholariq.org/institutions/kansai-medical-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.